Publications by authors named "Maurizio Azzurro"

Article Synopsis
  • The study examines the risk of colorectal cancer (CRC) after the removal of low-risk and high-risk adenomas in patients who tested positive for fecal immunochemical tests (FIT) and underwent colonoscopy in Italy from 2002 to 2017.
  • Researchers tracked 87,248 colonoscopy cases and found that those with high-risk adenomas had a significant increase in CRC incidence compared to those with negative colonoscopies, while those with low-risk adenomas did not show increased risk.
  • The presence of specific risk factors such as the location and morphology of the adenomas, particularly in high-risk cases, contributed to the higher incidences of CRC observed in the follow-up period.
View Article and Find Full Text PDF

Background: Colorectal cancer (CRC) screening programs based on fecal immunochemical tests (FITs) represent the standard of care for population-based interventions. Their benefit depends on the identification of neoplasia at colonoscopy after FIT positivity. Colonoscopy quality measured by adenoma detection rate (ADR) may affect screening program effectiveness.

View Article and Find Full Text PDF

The analysis was conducted to assess the pharmacological costs of regorafenib and trifluridine/tipiracil in the treatment of refractory metastatic colorectal cancer (mCRC). Pivotal phase III randomized controlled trials (RCTs) of regorafenib and trifluridine/tipiracil in the treatment of refractory mCRC were considered. We have also considered the ReDOS trial, in order to verify if the dose-escalation strategy (practice changing for regorafenib) could influences the results.

View Article and Find Full Text PDF

Background And Study Aims: The high volume and poor palatability of 4 L of polyethylene glycol (PEG)-based bowel cleansing preparation required before a colonoscopy represent a major obstacle for patients. The aim of this study was to compare two low volume PEG-based preparations with standard 4 L PEG in individuals with a positive fecal immunochemical test (FIT) within organized screening programs in Italy.

Patients And Methods: A total of 3660 patients with a positive FIT result were randomized to receive, in a split-dose regimen, 4 L PEG or 2 L PEG plus ascorbate (PEG-A) or 2 L PEG with citrate and simethicone plus bisacodyl (PEG-CS).

View Article and Find Full Text PDF